Ideon Science ParkIdeon Science Park

EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform

Share

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform.

EXINI has entered into a global software licensing agreement with GE Healthcare for the rights to EXINI bone, a vendor neutral stand-alone variant of aBSI that is enabled with artificial intelligence. Under the terms of the non-exclusive agreement EXINI will receive tiered licensing fees per license sold.

Read more here.

Automated Bone Scan Index (aBSI)

The automated Bone Scan Index (aBSI) technology, developed by EXINI Diagnostics AB, gives a fully quantitative assessment of bone scans that incorporates inferred masses of all lesions. As of 2017, aBSI is provided as a secure and compliant web application readily available from a web browser by logging in to www.bonescanindex.com.  In Europe, the device is CE-marked according to MDD 93/42 EEC, and is available for clinical use in Austria, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland, and UK. As of October 2019, aBSI is also available for clinical use in the United States with a 510(k) clearance (K191262). aBSI is also available for local installation under the name EXINI bone. As of January 2019, EXINI bone is CE marked according to MDD 93/42 EEC.

EXINI Diagnostics AB

EXINI Diagnostics AB was established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumor burden in patients with metastatic prostate cancer. This platform has been installed at about 1,000 hospitals worldwide. In 2015, EXINI was acquired by Progenics Pharmaceuticals Inc. for developing patient centric AI technologies for PSMA-targeted theranostic agents. In 2020, Progenics Pharmaceuticals, Inc. was acquired by Lantheus Holdings, Inc.

www.exini.com

Images

Links

About Ideon Science Park

Ideon Science Park
Ideon Science Park
Scheelevägen 15
22370 Lund

+46 46 286 85 00https://ideon.se/

Ideon Science park har kommit att bli en plats där framstående innovationer skapas och spännande tillväxtbolag tar avstamp. Multinationella företag som Axis, Ericsson och Qlik härstammar från Ideon som grundades 1983 i samarbete med Lunds universitet. Flera av världens största innovationsbolag har utvecklingskontor eller samarbetsinvesteringar på området. På Ideon finns en unik mix av kompetenscentra, vilket är vår stora styrka i en värld där branscherna glider samman. Här finns också tillgång till laboratorier av högsta standard, vilket gör Ideon Science Park till en dynamisk tillväxt- och kunskapsmiljö för utvecklings- och forskningsbolag i världsklass. Ideon Science Park arbetar med fyra fokusområden; Future Transportation, Smart Cities, Connected Health och Smart Materials.

Subscribe to releases from Ideon Science Park

Subscribe to all the latest releases from Ideon Science Park by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Ideon Science Park

Ideon stipentiet 2021 går till Recilio - digitalt stöd för mental hälsa och motståndskraftiga organisationer1.6.2021 14:44:59 CEST | Pressmeddelande

Vinnare av 2021 års Ideon Stipendium på 25 000 SEK är startupföretaget Recilio på inkubatorn Ideon innovation. Grundarna Lisa Granath, CEO, Ida Wikholm, COO, Eugen Groh, HOS, samt deras diversifierade team visar höga ambitioner och starka entreprenörsegenskaper och har gjort stora framsteg på inkubatorn Ideon Innovation. Stipendiet är till minne av Ideon Societeten, en stiftelse som nu är nedlagd, men som bestod av viktiga personer för Ideons uppstart 1983.

Ideon Science Park engages 30 growth leaders to support Scaleups29.4.2021 14:43:38 CEST | Press release

Ideon Science Park is investing in the growth of Skåne (South of Sweden) though a well proven concept that leads to an average of 25% growth for the companies having participated in the program. Since last fall Ideon Science Park has an agreement with Navigator Scaleup that won an award as the best accelerator program in EU. Ideon is the south node in a national investment supported by Sparbankernas Riksförbund, a national bank foundation. 9 out of 10 company are started in the pilot phase and 30 experiences growth leaders have been engaged to contribute with their competence. Ideon Science Park is now looking for the 10th company - there is one place left saved for a female founder of a scaleup company. The project is being financed by Region Skåne and Wihlborgs Real Estates.

Dessa 30 tillväxtledare hjälper 10 skånska scaleups att växa7.4.2021 08:00:00 CEST | Pressmeddelande

Ideon Science Park satsar på att öka tillväxten i Skåne genom ett beprövat koncept som leder till 25% tillväxt i snitt efter programmet. Sedan i höstas har Ideon Science Park avtal med Navigator Scaleup, som vunnit EU pris som bästa acceleratorprogram. Ideon utgör dess sydligaste nod i en nationell satsning stöttat av Sparbankernas Riksförbund. 9 bolag av 10 i en pilotfas har startats och 30 erfarna tillväxtledare har engagerat sig för att hjälpa till med sin kompetens. Nu letar Ideon Science Park efter det tionde bolaget - det finns en plats kvar för ett ägarlett bolag med kvinnlig grundare. Projektet finansieras av Region Skåne och Wihlborgs fastigheter.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom